Welcome!

News Feed Item

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703975/Coronary-Arteriosclerosis-Global-Clinical-Trials-Review-H2-2014.html

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014" provides data on the Coronary Arteriosclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Arteriosclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Arteriosclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Coronary Arteriosclerosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Coronary Arteriosclerosis 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Coronary Arteriosclerosis Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Pfizer Inc. 31
Clinical Trial Overview of Pfizer Inc. 31
Merck & Co., Inc. 32
Clinical Trial Overview of Merck & Co., Inc. 32
Eli Lilly and Company 33
Clinical Trial Overview of Eli Lilly and Company 33
Cytori Therapeutics, Inc. 34
Clinical Trial Overview of Cytori Therapeutics, Inc. 34
C. H. Boehringer Sohn AG & Co. KG 35
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 35
AstraZeneca PLC 36
Clinical Trial Overview of AstraZeneca PLC 36
MDDX LLC 37
Clinical Trial Overview of MDDX LLC 37
Innovaderm Research Inc. 38
Clinical Trial Overview of Innovaderm Research Inc. 38
CardioVascular BioTherapeutics, Inc. 39
Clinical Trial Overview of CardioVascular BioTherapeutics, Inc. 39
Avant Immunotherapeutics, Inc 40
Clinical Trial Overview of Avant Immunotherapeutics, Inc 40
Clinical Trial Overview of Top Institutes / Government 41
National Heart, Lung, and Blood Institute 41
Clinical Trial Overview of National Heart, Lung, and Blood Institute 41
Providence VA Medical Center 42
Clinical Trial Overview of Providence VA Medical Center 42
National Taiwan University Hospital 43
Clinical Trial Overview of National Taiwan University Hospital 43
Seoul National University Hospital 44
Clinical Trial Overview of Seoul National University Hospital 44
Rigshospitalet 45
Clinical Trial Overview of Rigshospitalet 45
University of Ottawa Heart Institute 46
Clinical Trial Overview of University of Ottawa Heart Institute 46
University of California, San Diego 47
Clinical Trial Overview of University of California, San Diego 47
University of Minnesota 48
Clinical Trial Overview of University of Minnesota 48
Massachusetts General Hospital 49
Clinical Trial Overview of Massachusetts General Hospital 49
U.S. Department of Veterans Affairs 50
Clinical Trial Overview of U.S. Department of Veterans Affairs 50
Five Key Clinical Profiles 51
Appendix 81
Abbreviations 81
Definitions 81
Research Methodology 82
Secondary Research 82
About GlobalData 83
Contact Us 83
Disclaimer 83
Source 83

List of Tables
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Coronary Arteriosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Coronary Arteriosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Coronary Arteriosclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Coronary Arteriosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Coronary Arteriosclerosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Coronary Arteriosclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Coronary Arteriosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 31
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 32
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 33
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytori Therapeutics, Inc., 2014* 34
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 35
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 36
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by MDDX LLC, 2014* 37
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Innovaderm Research Inc., 2014* 38
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by CardioVascular BioTherapeutics, Inc., 2014* 39
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Avant Immunotherapeutics, Inc, 2014* 40
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 41
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Providence VA Medical Center, 2014* 42
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 43
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2014* 44
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Rigshospitalet, 2014* 45
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Ottawa Heart Institute, 2014* 46
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2014* 47
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2014* 48
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 49
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 50

List of Figures
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Coronary Arteriosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Coronary Arteriosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Coronary Arteriosclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Coronary Arteriosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Coronary Arteriosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 82

Read the full report:
Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703975/Coronary-Arteriosclerosis-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
Digital Transformation and Disruption, Amazon Style - What You Can Learn. Chris Kocher is a co-founder of Grey Heron, a management and strategic marketing consulting firm. He has 25+ years in both strategic and hands-on operating experience helping executives and investors build revenues and shareholder value. He has consulted with over 130 companies on innovating with new business models, product strategies and monetization. Chris has held management positions at HP and Symantec in addition to ...
"We do one of the best file systems in the world. We learned how to deal with Big Data many years ago and we implemented this knowledge into our software," explained Jakub Ratajczak, Business Development Manager at MooseFS, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Today, we have more data to manage than ever. We also have better algorithms that help us access our data faster. Cloud is the driving force behind many of the data warehouse advancements we have enjoyed in recent years. But what are the best practices for storing data in the cloud for machine learning and data science applications?
All zSystem customers have a significant new business opportunity to extend their reach to new customers and markets with new applications and services, and to improve the experience of existing customers. This can be achieved by exposing existing z assets (which have been developed over time) as APIs for accessing Systems of Record, while leveraging mobile and cloud capabilities with new Systems of Engagement applications. In this session, we will explore business drivers with new Node.js apps ...
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
The technologies behind big data and cloud computing are converging quickly, offering businesses new capabilities for fast, easy, wide-ranging access to data. However, to capitalize on the cost-efficiencies and time-to-value opportunities of analytics in the cloud, big data and cloud technologies must be integrated and managed properly. Pythian's Director of Big Data and Data Science, Danil Zburivsky will explore: The main technology components and best practices being deployed to take advantage...
For years the world's most security-focused and distributed organizations - banks, military/defense agencies, global enterprises - have sought to adopt cloud technologies that can reduce costs, future-proof against data growth, and improve user productivity. The challenges of cloud transformation for these kinds of secure organizations have centered around data security, migration from legacy systems, and performance. In our presentation, we will discuss the notion that cloud computing, properl...
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities - ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups.
The Internet of Things is clearly many things: data collection and analytics, wearables, Smart Grids and Smart Cities, the Industrial Internet, and more. Cool platforms like Arduino, Raspberry Pi, Intel's Galileo and Edison, and a diverse world of sensors are making the IoT a great toy box for developers in all these areas. In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists discussed what things are the most important, which will have the most profound e...
"MobiDev is a Ukraine-based software development company. We do mobile development, and we're specialists in that. But we do full stack software development for entrepreneurs, for emerging companies, and for enterprise ventures," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Digital Transformation is well underway with many applications already on the cloud utilizing agile and devops methodologies. Unfortunately, application security has been an afterthought and data breaches have become a daily occurrence. Security is not one individual or one's team responsibility. Raphael Reich will introduce you to DevSecOps concepts and outline how to seamlessly interweave security principles across your software development lifecycle and application lifecycle management. With ...
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...